We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+21.92%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.44B
AUM Growth
+$302M
Cap. Flow
+$191M
Cap. Flow %
13.26%
Top 10 Hldgs %
50.32%
Holding
229
New
57
Increased
37
Reduced
31
Closed
55

Top Buys

Rank Stock Value
1
NXTM
NxStage Medical Inc.
NXTM
+$24.7M
2
MDVN
MEDIVATION, INC.
MDVN
+$23.8M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$18.4M
4
STJ
St Jude Medical
STJ
+$16.6M
5
LJPC
La Jolla Pharmaceutical Company
LJPC
+$11.4M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$41.5M
2
HUM icon
Humana
HUM
+$20.1M
3
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$12.4M
4
BAX icon
Baxter International
BAX
+$9.04M
5
XLRN
Acceleron Pharma
XLRN
+$6.5M

Sector Composition

Rank Sector Weight
1 Healthcare 78.68%
2 Consumer Staples 0.52%
3 Consumer Discretionary 0.08%
4 Financials 0.04%
5 Industrials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SIOX
51
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$6.23M 0.43%
60,625
– –
ZYNE
52
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$5.82M 0.4%
849,350
– –
FWP
53
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$5.66M 0.39%
44,486
+17,872
+67% +$2.41M
ACAD icon
54
Acadia Pharmaceuticals
ACAD
$5.27B
$5.36M 0.37%
165,240
-90,000
-35% -$3.01M
SUPN icon
55
Supernus Pharmaceuticals
SUPN
$2.64B
$5.09M 0.35%
250,000
+50,000
+25% +$887K
FOMX
56
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$5.05M 0.35%
+795,000
New +$5.28M
CLLS
57
Cellectis
CLLS
$344M
$4.88M 0.34%
183,507
+180,511
+6,025% +$5.29M
ARCT icon
58
Arcturus Therapeutics
ARCT
$439M
$4.62M 0.32%
146,896
– –
NEOS
59
DELISTED
Neos Therapeutics, Inc
NEOS
$4.61M 0.32%
626,876
+526,876
+527% +$5.03M
ANTH
60
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$4.61M 0.32%
186,520
– –
OTLK icon
61
Outlook Therapeutics
OTLK
$155M
$4.46M 0.31%
+8,205
New +$4.89M
CLSD
62
DELISTED
Clearside Biomedical
CLSD
$4.45M 0.31%
+42,321
New +$4.44M
ASMB icon
63
Assembly Biosciences
ASMB
$719M
$4.41M 0.31%
66,250
– –
NDRM
64
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$4.39M 0.3%
270,000
– –
TSRO
65
PUT
DELISTED
TESARO, Inc.
TSRO
$4.2M 0.29%
+50,000
New +$2.23M
ABEO icon
66
Abeona Therapeutics
ABEO
$355M
$4.16M 0.29%
70,515
– –
AGRX
67
DELISTED
Agile Therapeutics
AGRX
$3.91M 0.27%
257
+169
+192% +$2.31M
ANIP icon
68
ANI Pharmaceuticals
ANIP
$1.74B
$3.75M 0.26%
67,161
-46,899
-41% -$2.28M
ELDN icon
69
Eledon Pharmaceuticals
ELDN
$282M
$3.64M 0.25%
4,081
+1,085
+36% +$1.2M
GNVC
70
DELISTED
GenVec, Inc.
GNVC
$3.45M 0.24%
60,664
– –
CASC
71
DELISTED
Cascadian Therapeutics, Inc.
CASC
$3.22M 0.22%
569,020
– –
KA
72
DELISTED
Kineta, Inc. Common Stock
KA
$3.03M 0.21%
1,786
– –
AVEO
73
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$2.99M 0.21%
+310,881
New +$3M
INNL
74
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$2.81M 0.19%
+560,000
New +$4.59M
CEMP
75
DELISTED
Cempra, Inc.
CEMP
$2.8M 0.19%
170,000
+20,000
+13% +$353K
1 2
3
4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q2 2016 Portfolio in Review

As of Q2 2016, Perceptive Advisors held 229 positions worth $1.44B, up 27% from $1.14B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors deployed $191M of net new capital in Q2 2016, opening 57 new positions and adding to 37 existing holdings. Its largest new stake was NxStage Medical Inc.: 1,382,410 shares worth $30M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 93% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Five Prime Therapeutics, Inc., an estimated $12.4M trimmed.

  • Perceptive Advisors's largest Q2 2016 buy was NxStage Medical Inc.: 1,382,410 shares worth $30M.
  • Perceptive Advisors added most to MEDIVATION, INC. in Q2 2016, an estimated $23.8M increase.
  • Perceptive Advisors's biggest Q2 2016 reduction was Five Prime Therapeutics, Inc., cutting an estimated $12.4M.
  • Perceptive Advisors fully exited Allergan plc in Q2 2016, selling an estimated $41.5M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $1.44B portfolio in Q2 2016.
  • Perceptive Advisors opened 57 new positions and closed 55 in Q2 2016.
  • Perceptive Advisors's portfolio value rose 27% quarter-over-quarter to $1.44B.

Based on Perceptive Advisors's 13F filing for Q2 2016, filed 11 Aug 2016.